IQVIA (NYSE:IQV) Sees Unusually-High Trading Volume - What's Next?

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) saw an uptick in trading volume on Monday . 3,129,111 shares traded hands during mid-day trading, an increase of 112% from the previous session's volume of 1,476,504 shares.The stock last traded at $154.18 and had previously closed at $148.99.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Truist Financial reduced their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. UBS Group lowered their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Robert W. Baird dropped their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $231.71.

IQVIA Stock Up 4.8%

The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business has a fifty day moving average of $163.91 and a 200 day moving average of $188.09. The stock has a market cap of $27.00 billion, a price-to-earnings ratio of 20.81, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $2.54 earnings per share. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Howard Capital Management Inc. grew its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after buying an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares in the last quarter. Cypress Wealth Services LLC increased its position in IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after acquiring an additional 57 shares during the last quarter. Harbor Investment Advisory LLC raised its stake in IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares during the period. Finally, Continuum Advisory LLC raised its holdings in shares of IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.